89bio, Inc. (ETNB) Dividend History

89bio, Inc. (ETNB) is a biotechnology company focused on developing and commercializing targeted therapies for rare and prevalent liver diseases. Founded to address unmet medical needs, the company leverages innovative scientific approaches to create treatments that improve patient outcomes.

142 Sansome Street, San Francisco, CA, 94104
Phone: (415) 432-9270
Website: https://www.89bio.com

Dividend History

89bio, Inc. currently does not pay dividends

Company News

89bio (ETNB) Q2 R&D Jumps 131%

89bio, a clinical-stage biotech company, reported a Q2 2025 net loss of $111.5 million, with increased R&D expenses driven by late-stage clinical trials for pegozafermin, a drug targeting metabolic and liver diseases. The company maintains substantial cash reserves of $561.2 million and continues advancing Phase 3 clinical studies.

The Motley Fool
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

GlobeNewswire Inc.

Featured Companies: ARWR BBIO CRNX IONS NBIX
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy

89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research
Madrigal’s stock surges as FDA approves first drug for liver disease MASH

Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.

MarketWatch

Featured Companies: AKRO LLY MDGL
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. SunOpta The Trade: SunOpta Inc. (NASDAQ: STKL) CEO Brian W ...

Benzinga

Featured Companies: IONQ STKL

Page data last updated 09/07/2025 01:31:13 UTC